BCDA.NASDAQBiocardia, INC

Form 4: BioCardia CEO Peter Altman Acquires Shares and Warrants in Private Placement

Sentiment:

SEC Form 4


BioCardia's President and CEO, Peter Altman, participated in a private placement, acquiring shares of common stock and warrants.

Capital raiseThe document details a private placement with certain qualified institutional buyers and institutional accredited investors.The Reporting Person received one share of common stock together with one warrant to purchase a share of common stock for each share of common stock purchased.

Summary

  • Peter Altman, the President and CEO of BioCardia, Inc., acquired 26,246 shares of common stock at a price of $1.905 per share on April 23, 2025.
  • This transaction was part of a private placement with qualified institutional buyers and institutional accredited investors.
  • Altman also received warrants to purchase 26,246 shares of common stock at an exercise price of $1.905, exercisable immediately and expiring on April 23, 2030.
  • Following the transaction, Altman directly owns 138,966 shares of BioCardia common stock and warrants for 71,516 shares.

Sentiment

Score: 6

Explanation: The CEO's participation in a private placement is generally a positive sign, suggesting confidence in the company. However, the overall impact depends on the context of the placement and the company's financial situation.

Positives

  • The CEO's participation in the private placement could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future performance. A purchase by the CEO is generally viewed positively.

Stakeholder Impact

  • Shareholders may view the CEO's purchase as a positive signal.
  • The private placement could impact the ownership structure of the company.

Key Dates

DateDescription
04/23/2025Date of the transaction: acquisition of shares and warrants in a private placement.
04/23/2030Expiration date of the warrants acquired in the private placement.
04/25/2025Date of the form filing.

Keywords

BioCardia, Peter Altman, private placement, common stock, warrants, insider trading, beneficial ownership, BCDA

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.